CN112996486A - 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病 - Google Patents

包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病 Download PDF

Info

Publication number
CN112996486A
CN112996486A CN201880059888.2A CN201880059888A CN112996486A CN 112996486 A CN112996486 A CN 112996486A CN 201880059888 A CN201880059888 A CN 201880059888A CN 112996486 A CN112996486 A CN 112996486A
Authority
CN
China
Prior art keywords
cpp
therapeutic agent
amd
rpe
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059888.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·罗伊兹曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN112996486A publication Critical patent/CN112996486A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201880059888.2A 2017-07-17 2018-07-17 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病 Pending CN112996486A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533231P 2017-07-17 2017-07-17
US62/533,231 2017-07-17
PCT/US2018/042410 WO2019018350A1 (en) 2017-07-17 2018-07-17 TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES

Publications (1)

Publication Number Publication Date
CN112996486A true CN112996486A (zh) 2021-06-18

Family

ID=63104068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059888.2A Pending CN112996486A (zh) 2017-07-17 2018-07-17 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病

Country Status (8)

Country Link
US (2) US10905770B2 (2)
EP (1) EP3654941A1 (2)
JP (1) JP2020528082A (2)
CN (1) CN112996486A (2)
AU (1) AU2018302022A1 (2)
CA (1) CA3070241A1 (2)
IL (1) IL272105A (2)
WO (1) WO2019018350A1 (2)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476587A (zh) * 2021-07-19 2021-10-08 河南大学 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用
CN114404429A (zh) * 2021-11-30 2022-04-29 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
CN116444678A (zh) * 2022-10-18 2023-07-18 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
CN118290598A (zh) * 2024-05-29 2024-07-05 深圳柏垠生物科技有限公司 重组纤连蛋白及其制备方法和应用
CN118995345A (zh) * 2024-08-09 2024-11-22 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
CN119792574A (zh) * 2025-01-10 2025-04-11 宁夏医科大学 一种仿生plga复合纳米材料及其制备方法与应用
WO2025218147A1 (zh) * 2024-08-09 2025-10-23 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200134287A (ko) * 2018-04-02 2020-12-01 젠켐 테크놀로지 컴퍼니 리미티드 (베이징) 타겟성을 구비하는 세포막 투과 펩타이드-다중팔 폴리에틸렌글리콜-약물 켤레체 및 그 응용
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
GB201900728D0 (en) * 2019-01-18 2019-03-06 Univ Birmingham Drug delivery system
US12115212B2 (en) * 2019-01-18 2024-10-15 L & J Bio Co., Ltd. Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque deposition in Alzheimer's disease using a cystatin C fusion protein
EP3934675A2 (en) * 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
WO2020252453A1 (en) * 2019-06-14 2020-12-17 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
WO2021087399A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
PL3886858T3 (pl) * 2019-12-19 2022-08-29 Active Biotech Ab Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物
WO2021173999A1 (en) * 2020-02-28 2021-09-02 Northwestern University Method of enhancing aqueous humor outflow and reducing intraocular pressure
US20230173024A1 (en) * 2020-04-01 2023-06-08 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
US11754753B2 (en) * 2020-04-27 2023-09-12 Coopervision International Limited Antioxidant contact lens
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN111671922B (zh) * 2020-07-23 2023-03-21 四川大学华西医院 两亲性梳形嵌段接枝共聚物基超声造影剂及其制备方法
CN114073774A (zh) * 2020-08-17 2022-02-22 奥朗生物医药有限公司 药物和野生型穿膜肽衍生物的组合物
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
MX2023003877A (es) * 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
MX2023004631A (es) * 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
US20230399378A1 (en) * 2020-10-28 2023-12-14 The Florey Institute Of Neuroscience And Mental Health Peptide-based delivery of agents
CN114790225B (zh) * 2021-01-26 2024-09-10 清华大学 一种新型内体逃逸肽及其应用
US20220287968A1 (en) * 2021-03-09 2022-09-15 Florida State University Research Foundation, Inc. Lipid vesicle-mediated delivery to cells
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
WO2022216785A1 (en) * 2021-04-06 2022-10-13 University Of South Florida Peptide-small interfering rna-hyaluronic acid nanoparticles and methods of use thereof
AU2022264438A1 (en) * 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CA3218251A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
CN113332450B (zh) * 2021-05-11 2023-08-04 铜仁学院 一种眼部给药递释系统氧化锌纳米粒的制备方法及其使用方法和应用
CA3220626A1 (en) * 2021-05-28 2022-12-01 Aleksandar SKUBAN Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
CN113925966B (zh) * 2021-09-17 2022-10-04 西安电子科技大学 快速响应型细胞核靶向纳米诊疗探针的制备方法
KR102795182B1 (ko) * 2022-02-18 2025-04-15 (주)메디톡스 탈모 치료 또는 발모 촉진 활성을 갖는 폴리펩티드 및 그의 용도
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis
WO2024156871A1 (en) * 2023-01-27 2024-08-02 Glasspearl Oü Mixtures of lipid nanoparticles and cell penetrating peptides
WO2024160819A1 (en) 2023-01-30 2024-08-08 Consorcio Centro De Investigación Biomédica En Red Nanoparticles with antibodies for ocular treatment
WO2024178368A2 (en) * 2023-02-23 2024-08-29 Ohio State Innovation Foundation Therapeutic protein combinations
CN116270974B (zh) * 2023-03-09 2024-03-12 湖南大学 一种组合物、阿柏西普递送系统和制备方法
TWI877652B (zh) * 2023-06-14 2025-03-21 長庚大學 眼用藥物遞送載體及其應用
WO2025093129A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain
WO2025128821A1 (en) * 2023-12-12 2025-06-19 Juvena Therapeutics, Inc. Compositions and methods for adp-ribosylation factor molecular trafficking
WO2025147589A1 (en) * 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders
WO2025212745A1 (en) * 2024-04-04 2025-10-09 University Of Massachusetts Engineered adeno-associated virus (aav) capsid protein and uses thereof
WO2026033482A1 (en) * 2024-08-08 2026-02-12 Universita' Degli Studi Di Torino Therapeutic contact lenses loaded with mucin-based nanoparticles
WO2026034435A1 (ja) * 2024-08-09 2026-02-12 東亞合成株式会社 ペプチドフラグメント及びその利用
CN119746027A (zh) * 2025-01-10 2025-04-04 山东济肽生物科技有限公司 多肽组合物的应用及治疗衰老相关皮肤病的组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266663A1 (en) * 2001-12-07 2004-12-30 Schwartz Daniel M. Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM)
CN104884049A (zh) * 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US20170000730A1 (en) * 2008-11-13 2017-01-05 Gholam A. Peyman Ophthalmic drug delivery method
WO2017066529A1 (en) * 2015-10-14 2017-04-20 Massachusetts Eye And Ear Infirmary High-dose statins for age-related macular degeneration
CN106668860A (zh) * 2015-11-09 2017-05-17 烟台大学 靶向眼后段的递药系统及其制剂和制备方法
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548114C2 (de) 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
ATE283013T1 (de) 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20070269379A1 (en) 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
EP2279177A1 (en) 2008-04-22 2011-02-02 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8691580B2 (en) 2010-04-09 2014-04-08 Merck Sharp & Dohme Corp. Single chemical entities and methods for delivery of oligonucleotides
EP2588127A4 (en) 2010-06-24 2014-06-11 Univ Indiana Res & Tech Corp DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
MX2014004953A (es) 2011-11-03 2014-05-28 Bayer Ip Gmbh Ligadores basados en tirosina para la conexion desprendible de peptidos.
US20140357563A1 (en) 2011-12-09 2014-12-04 The Children's Hospital Of Philadelphia Compositions and Methods for the Generation of Activated Protein C and Methods of Use Thereof
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
GB201401453D0 (en) 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201403268D0 (en) 2014-02-25 2014-04-09 Univ Birmingham Antimicrobial surface
CN117180445A (zh) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266663A1 (en) * 2001-12-07 2004-12-30 Schwartz Daniel M. Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM)
US20170000730A1 (en) * 2008-11-13 2017-01-05 Gholam A. Peyman Ophthalmic drug delivery method
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
CN104884049A (zh) * 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2017066529A1 (en) * 2015-10-14 2017-04-20 Massachusetts Eye And Ear Infirmary High-dose statins for age-related macular degeneration
CN106668860A (zh) * 2015-11-09 2017-05-17 烟台大学 靶向眼后段的递药系统及其制剂和制备方法

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476587A (zh) * 2021-07-19 2021-10-08 河南大学 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用
CN113476587B (zh) * 2021-07-19 2022-07-12 河南大学 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用
CN114404429A (zh) * 2021-11-30 2022-04-29 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
CN116444678A (zh) * 2022-10-18 2023-07-18 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
CN118290598A (zh) * 2024-05-29 2024-07-05 深圳柏垠生物科技有限公司 重组纤连蛋白及其制备方法和应用
CN118290598B (zh) * 2024-05-29 2024-09-27 深圳柏垠生物科技有限公司 重组纤连蛋白及其制备方法和应用
CN118995345A (zh) * 2024-08-09 2024-11-22 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
CN118995345B (zh) * 2024-08-09 2025-09-26 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
WO2025218147A1 (zh) * 2024-08-09 2025-10-23 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
CN119792574A (zh) * 2025-01-10 2025-04-11 宁夏医科大学 一种仿生plga复合纳米材料及其制备方法与应用

Also Published As

Publication number Publication date
AU2018302022A1 (en) 2020-02-27
CA3070241A1 (en) 2019-01-24
EP3654941A1 (en) 2020-05-27
IL272105A (en) 2020-03-31
US20190015521A1 (en) 2019-01-17
US10905770B2 (en) 2021-02-02
WO2019018350A1 (en) 2019-01-24
US20210085797A1 (en) 2021-03-25
JP2020528082A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
US10905770B2 (en) Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
JP2020528082A5 (2)
EP3570888A1 (en) Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CN110545836A (zh) 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病
US10426817B2 (en) Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
US11413322B2 (en) Immunotherapy for angiogenic disease
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
JP2015515282A (ja) 創傷治癒および組織修復のための組成物および方法
EP3238746B1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
CN109789180A (zh) Kif13b衍生的肽和抑制血管生成的方法
US20230340024A1 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
JP7356994B2 (ja) 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
US20240299564A1 (en) Peptide carriers and delivery to the eye of a subject
JP2022552217A (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
HK40011780A (en) Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
EP2816056A1 (en) Ameliorating agent for blood-brain barrier dysfunction
Mohite et al. Recent Updates in Synthetic and Biological Molecules for Treatment/Therapy of Macular Degeneration Drugs
FR3046355A1 (fr) Fragments du facteur h pour son utilisation comme agent anti-angiogenique
Baid Lens epithelium derived growth factor (1-326): a new protein drug for retinal diseases
WO2023242844A1 (en) Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
EA048046B1 (ru) Новый пептид, композиции и способ доставки агентов в клетки и ткани
JP2022530632A (ja) 網膜変性疾患及び／又は組織傷害を処置するための短鎖合成ペプチド及びその使用
HK1245149B (en) Wt1 immunotherapy for intraocular angiogenic disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210618